Jindal Capital Fund Raise of ₹16.22 Cr

Jindal Capital Capital Structure Change

Jindal Capital's board approved rights issue terms for up to Rs 16.22 Crore. The issue opens 17 November 2026 and closes 1 December 2026.

Value

₹16.22 Cr

Execution

Issue opens 17 November 2026, closes 1 December 2026

Jindal Capital Board Meeting Date

Jindal Capital will hold a board meeting on November 2, 2026 to consider its rights issue terms. Trading window closes from October 28, 2026.

Jindal Capital Other Announcement

Jindal Capital Ltd submitted its quarterly shareholding pattern filing as required under SEBI regulations. The data provides the latest promoter and public shareholding details.

Jindal Capital Management Change

Jindal Capital Limited regularised Mr. Nischal Mittal from Additional Director to Independent Director. This change took effect on September 30, 2026.

Jindal Capital Other Announcement

Jindal Capital informed physical shareholders to update their PAN, KYC, nomination, and bank details with the RTA as per SEBI guidelines.

Jindal Capital Annual General Meeting

Jindal Capital Limited held its 32nd Annual General Meeting on September 30, 2026. Shareholders approved financial statements, director appointments, and a borrowing limit of Rs. 500 Crores.

Rajkot Investment Trust Fund Raise of ₹48 Cr

Rajkot Investment Trust's board approved a Rs 48 Crore rights issue of equity shares. Pricing and record date will be set later by a committee.

Value

₹48.00 Cr

U Y Fincorp Fund Raise of ₹187.2 Cr

U.Y. Fincorp's board approved preferential issues of warrants and equity shares aggregating Rs 187.17 Crore. The issue is subject to shareholder and regulatory approvals.

Value

₹187.2 Cr

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026